Autolus Therapeutics (AUTL) COO details initial shares, options and RSUs
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc Chief Operating Officer Christopher Andrew Vann filed an initial ownership report showing a mix of ordinary shares, American Depositary Shares (ADSs), options and restricted share units (RSUs).
He directly holds 152,211 Ordinary Shares and 40,000 ADSs, with each ADS currently representing one ordinary share and being convertible on a one-for-one basis. He also has several option awards over ADSs, including 500,000 ADSs at an exercise price of $1.89 expiring in 2035 and 375,000 ADSs at $1.46 expiring in 2036, alongside other grants at higher exercise prices with earlier expirations. In addition, he holds 83,300 RSUs, each representing a right to receive one ADS. Certain options are already fully vested and exercisable, while others and the RSUs vest over multi-year schedules in equal installments.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Vann Christopher Andrew
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 40,000 shares (Direct);
Share Option (right to buy) — 43,956 shares (Direct);
Restricted Share Units — 83,300 shares (Direct);
Ordinary Shares — 152,211 shares (Direct)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. Fully vested and exercisable. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
FAQ
What does the Form 3 filing for Autolus Therapeutics (AUTL) show for Christopher Vann?
The Form 3 filing shows Chief Operating Officer Christopher Andrew Vann’s initial ownership in Autolus Therapeutics, including ordinary shares, ADSs, stock options and RSUs. It establishes his starting equity position as a reporting insider under SEC rules.
What option awards over Autolus Therapeutics ADSs does Christopher Vann report?
Vann reports several Share Option (right to buy) grants over ADSs, including 500,000 ADSs at $1.89 expiring in 2035 and 375,000 ADSs at $1.46 expiring in 2036, plus additional options at higher exercise prices and earlier expirations.
How do Christopher Vann’s options and RSUs in AUTL vest over time?
Some options are fully vested and exercisable, while others vest 25% on a stated date with the remainder in 36 equal monthly installments. The 83,300 RSUs vest in four equal annual installments beginning on January 26, 2027, each delivering one ADS.
What are the key RSU holdings reported for Autolus Therapeutics COO Christopher Vann?
The Form 3 shows Vann holding 83,300 restricted share units, each representing a contingent right to receive one Autolus ADS. These RSUs vest in four equal annual installments starting on January 26, 2027, adding time-based, stock-settled compensation to his equity mix.